Rate Contract vs Tender vs Direct Purchase: A Route Policy

A rate contract fixes a supplier and a price for a defined period without committing to a quantity, so individual requirements convert into a supply order rather than a fresh competitive process. For high-frequency, stable-specification items this is the single biggest reduction in procurement cycle time available to a hospital. Gloves, syringes, IV fluids, common oral formulations and general surgical disposables are the natural population.

The cost is rigidity in a moving market. If input prices fall, you are paying yesterday's rate until the contract expires, and the supplier has no incentive to renegotiate. If prices rise sharply, the supplier starts under-supplying, quoting stock unavailability, and pushing you to the spot market where the same firm sells at the higher rate. Both failure modes are common enough that a rate contract without a price-variation clause and a minimum fill-rate obligation is only half a contract.

Rate contracts also concentrate risk. One supplier holding the annual requirement for a critical item is a single point of failure against a factory shutdown, a regulatory action, or a batch recall. For the items where a stockout has clinical consequences, split the award between two suppliers on a defined ratio even if the second rate is marginally higher. The premium is an insurance cost and should be described that way to the finance committee.

Open tendering is the most defensible route and the most expensive in staff time. Publication, pre-bid clarification, technical evaluation, financial opening, comparative statement, committee approval and award can consume weeks. That expense is worth paying when the annual value is large, the market is genuinely competitive, and the specification can be written unambiguously. It is wasted on a low-value item with two possible suppliers.

Limited tender, where a defined list of pre-qualified suppliers is invited, sits between the two. Its integrity depends entirely on how the supplier list was built and how often it is refreshed. A list assembled five years ago and never revisited is not a limited tender, it is a closed shop with paperwork. Refresh the panel on a stated cycle through an open expression-of-interest exercise, and record the qualification basis for every firm on it.

The uncomfortable truth about tendering in clinical categories is that lowest-price awards create quality problems that surface in the ward, not in the finance department. A glove that tears, a cannula that leaks, a suture that frays — the cost lands as a clinical incident and a wastage figure that never gets traced back to the award. Two-envelope evaluation with a real technical threshold, and a sample trial before award for items with a user-experience dimension, are the counterweights.

Direct purchase exists because clinical need does not wait for a tender cycle. A patient on the table needs the implant now. A ventilator circuit fails at two in the morning. The route is legitimate; what turns it into an audit finding is the absence of a monetary ceiling, a defined approver, and a post-facto ratification step. Write all three into the policy and the route becomes controlled rather than exceptional.

Set the ceiling by item class and by urgency, not by a single global figure. A blanket ceiling low enough to control stationery is too low for an emergency implant, and one high enough for the implant is far too high for stationery. Two or three bands, each with a named approver and a documentation requirement proportionate to the value, covers almost every real situation without producing a policy nobody reads.

The metric that matters is the share of annual spend flowing through the emergency route. If it climbs above the level your policy anticipated, the problem is not procurement discipline; it is planning. Emergency purchase volume is a diagnostic for weak forecasting, late tender cycles, or reorder levels set on optimism. Report it monthly with the top five items by emergency spend, and you will usually find three items that simply need a rate contract.

A route policy is only usable if every item in your master carries the attributes the policy keys on. At minimum that means annual consumption value, criticality of stockout, shelf life, the number of qualified suppliers, and whether the item is price-controlled or scheme-reimbursed. Most hospital item masters carry none of these fields, which is why the policy exists on paper and the buying happens on instinct.

The segmentation work is a one-time push followed by maintenance. Take the twelve months of issue data you already have, rank items by consumption value, and tag the top band. Ask the pharmacy and therapeutics committee and the nursing leadership to mark criticality independently of value, because the two do not correlate — a low-value item with a clinical consequence on stockout deserves rate-contract treatment more than a high-value item with three days of tolerance.

Then attach the route. High value plus competitive market goes to open tender. High frequency plus stable specification goes to rate contract. Critical plus narrow supplier base goes to dual-source rate contract with a mandatory buffer. Low value plus low criticality goes to direct purchase within the ceiling. Anything that does not fit is escalated to the committee, and the exceptions become next year's policy amendments.

Keep it short enough to be read. A route policy that runs to forty pages will be quoted by nobody and applied by nobody. The working version is a matrix of item classes against routes, a page of definitions, a page of approval limits by designation, and a page on exception handling. Anything longer belongs in annexures that the policy references rather than in the body.

Name roles, not people. The policy should say that a purchase between two stated bands is approved by the medical superintendent, not by an individual, so it survives staff turnover. Similarly, state the composition of the purchase committee by designation and set a quorum, because a committee that cannot form does not approve, and unapproved purchases become the emergency route by default.

Version it and review it annually against your own data. Pull the year's purchases, classify them by route actually used, and compare against the route the policy prescribes. The gaps tell you where the policy is unrealistic. A policy revised annually against evidence carries far more weight in a NABH assessment than one signed three years ago and never tested, because the assessor is looking for a system that is used, not a document that exists.

Splitting a requirement to stay under a direct purchase ceiling is the most common integrity failure in hospital procurement, and it is almost always well intentioned. A buyer facing a six-week tender cycle for an item the ward needs next Tuesday splits the order into three. The control is not moral exhortation; it is a system that flags multiple orders for the same item to the same supplier within a short window, and a route policy whose tender cycle is realistic enough that splitting is not tempting.

The second is that route choice determines your negotiating position for the next three years. Award a rate contract with no exit and no performance obligation, and you have handed a supplier an annuity. Award an open tender with a technical threshold set too low, and you have taught the market that price is all you evaluate. Suppliers learn from your behaviour faster than your team does.

The third is that the route policy needs a clinical owner as well as a materials owner. Specification quality, criticality tagging and substitution decisions are clinical judgements dressed in procurement language. A policy written entirely inside the materials department will be technically sound and clinically wrong on exactly the items where being wrong is expensive.